Quick Stats for Obesity GLP-1 Market Obesity GLP-1 Market Value (2025): USD 8,169 million Obesity GLP-1 Market Forecast Value (2035): USD 65,364 million Obesity GLP-1 Market Forecast CAGR: 23.1% Leading Molecule Class in Obesity GLP-1 Market: Semaglutide (58.0%) Key Growth Regions in Obesity GLP-1 Market: North America, Europe, and East Asia Top Key Players in Obesity GLP-1 Market: Novo Nordisk, Eli Lilly, and emerging manufacturers Between 2025 and 2030, the obesity GLP-1 market is projected to expand from USD 8169.0 million to USD 39,528 million, resulting in a value increase of USD 31359.0 million, which represents 54.8% of the total forecast growth for the decade
Personalize Your Formula Your Options, Clearly Explained Choosing a medication doesn't have to be complex
Thus, more prospective clinical studies on non-diabetic obese patients are needed
The starting dose of retatrutide in clinical trials is 1 mg once weekly for the first 4 weeks
High Molecular Complexity: A long amino acid sequence enables detailed investigations of receptor binding and intracellular signaling
if confirmed, the medication should not be restarted) [1] You develop right-upper abdominal pain, jaundice (yellowing of skin/eyes), pale stools or dark urine (possible gallbladder disease) You develop chest pain, severe breathlessness, or signs of allergic reaction Joint pain follows trauma or injury with suspected fracture Your healthcare provider may undertake investigations including blood tests (inflammatory markers, rheumatoid factor, uric acid), X-rays, or referral to rheumatology if inflammatory arthritis is suspected
